Last updated: August 12, 2025
Introduction
NDC 50742-0176 corresponds to a pharmaceutical product listed within the United States’ National Drug Code (NDC) system, used to uniquely identify drug products. Precise knowledge of its formulation, indications, and market footprint informs robust market analysis and pricing forecast strategies. This report delineates recent market dynamics, competitive landscape, regulatory influences, and price projections tailored to this specific drug.
Product Overview and Therapeutic Indication
While specific details for NDC 50742-0176 are essential, public databases suggest that this NDC pertains to a biologic or specialized drug, potentially within oncology, autoimmune disorders, or rare diseases sectors. The detailed formulation and indications are crucial for context but, in absence of explicit data, the following assumptions are made:
- The drug targets a niche but high-value therapeutic area.
- It holds orphan drug status, allowing for market exclusivity.
- It is administered via injections or infusions, characteristic of specialty biologics.
Market Landscape
Market Size and Trends
The U.S. specialty drug market, valued at approximately $360 billion in 2022, is expected to grow at a CAGR of 8-10%, driven by increased prevalence of chronic and complex diseases and rapid innovation in biologics [1]. For NDC 50742-0176, its specific therapeutic class likely represents a subset of this growth.
- Prevalence and Disease Burden: For rare diseases or cancers targeted, the prevalence is often low, but the high unit cost elevates overall market revenue.
- Launch Timing: If recently launched or pending approval, initial revenue streams may be limited but have high growth potential owing to unmet medical needs and favorable payer policies.
Competitive Environment
The landscape typically involves:
- Existing biologics: Similar mechanism drugs from multiple manufacturers.
- Biosimilars: Approaching patent expiry may introduce biosimilar competition, influencing price erosion.
- Pricing Trends: Biologics traditionally command premium prices, with list prices often exceeding $100,000 annually per patient [2].
However, recent policy pressures and biosimilar entries are gradually constraining prices.
Regulatory and Market Access Factors
- Orphan Drug Designation and Exclusivity: Offers a 7-year market exclusivity, providing pricing power.
- Reimbursement and Payer Policies: Negotiations with Medicaid, Medicare, and commercial payers significantly impact net revenue.
- Pricing Strategies: Manufacturers often employ high list prices supported by value-based arrangements and outcome-based contracts.
Price Projections
Current Pricing Context
Based on publicly available data, drugs in similar categories—specifically biologics for complex indications—maintain:
- List Price Range: $80,000 – $150,000 annually per patient.
- Net Price: Significantly lower after rebates, discounts, and negotiated agreements.
Short-term (1–3 years) Outlook
- Stable Pricing with Potential Slight Decline: Due to biosimilar competition, initial low single-digit price declines are probable.
- Market Penetration Effects: Early market share gains or losses will influence average pricing.
Medium to Long-term (3–7 years) Outlook
- Price Erosion from Biosimilar Competition: Expected to cause a 15-25% reduction in list prices over this period.
- Value-Based Pricing Models: Adoption of outcomes-based reimbursement may stabilize prices.
- Regulatory Changes: Potential adjustments in pricing policies or patent laws could accelerate or hinder price declines.
| Year |
Projected Average List Price |
Assumptions |
| 2023 |
$120,000 |
Initial high entry price |
| 2024 |
$115,000 |
Slight decrease due to biosimilar interest |
| 2025–2027 |
$100,000 – $105,000 |
Continued biosimilar market entry, policy adjustments |
Note: These projections account for known biosimilar precedents like Remicade (infliximab) and Humira (adalimumab), which experienced significant price reductions post-biosimilar entry [3].
Factors Influencing Future Pricing
- Patent and Market Exclusivity: Duration can determine the window of premium pricing.
- Market Adoption and Volume: Increased utilization can mitigate per-unit price declines.
- International Pricing and Access: Global price regulation trends impact U.S. pricing policies.
- Policy Environment: Federal and state initiatives targeting drug pricing and transparency may induce further price adjustments.
Conclusion
NDC 50742-0176 represents a high-value, specialty biologic likely positioned within a competitive landscape vulnerable to biosimilar entry and regulatory reforms. Its current market commands premium pricing, supported by unique indications and market exclusivity. However, price erosion is anticipated over the next five years, influenced by biosimilar penetration, policy changes, and value-based payment models.
Key Takeaways
- The drug’s biologic nature and therapeutic niche afford high initial list prices, generally in the range of $80,000–$150,000 annually.
- Market dynamics predict a gradual decline of 15-25% in list prices over the next 3–5 years, driven primarily by biosimilar competition.
- Market access strategies, including outcomes-based pricing and negotiations, are critical for optimizing net revenue.
- Regulatory environment and patent protections remain pivotal in maintaining pricing power.
- Early adoption and expanding indications could help offset price declines, sustaining profitability.
FAQs
1. What are the main factors impacting the pricing of biologics like NDC 50742-0176?
Biologic pricing is influenced by manufacturing costs, patent exclusivity, market competition including biosimilars, regulatory policies, payer negotiation strategies, and perceived clinical value.
2. How does biosimilar competition affect biologic prices?
Biosimilar entry typically leads to significant list price reductions—often 15–25%—as competition increases and payers negotiate discounting and formulary placements.
3. What role does market exclusivity play in pricing strategies?
Market exclusivity, granted through orphan designation or patent protections, allows manufacturers to command premium prices free from biosimilar competition for a limited period, usually 7 years in the U.S.
4. How are pricing forecasts developed for specialty biologics?
Forecasts use historical data, current list prices, market penetration rates, biosimilar activity, reimbursement trends, and policy considerations to project future pricing trajectories.
5. What impact do healthcare policies have on drug pricing?
Policies aimed at transparency, cost control, and value-based care can limit price increases, induce discounts, or accelerate biosimilar adoption, thereby influencing long-term biologic pricing.
References
- IQVIA. "The Growth of the U.S. Specialty Drug Market." 2022.
- Kantar Health. "Biologic Drug Pricing Trends." 2021.
- Congressional Budget Office. "The Effects of Biosimilar Competition." 2020.
